ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

Home ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Phase II Trial of nab-sirolimus in Patients with Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update
Pacific pride: Abraxis veteran grooms dormant Celgene drug for success
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Aadi Bioscience to Participate in Upcoming Investor Conferences
Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Read More
Dave Lennon, PhD

Comments

Comments are closed.